- Home
- NSTS vs BLRX Comparison
NSTS vs BLRX Comparison
Compare NSTS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- BLRX
- Stock Information
- Founded
- NSTS 1921
- BLRX 2003
- Country
- NSTS United States
- BLRX Israel
- Employees
- NSTS N/A
- BLRX N/A
- Industry
- NSTS Savings Institutions
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- BLRX Health Care
- Exchange
- NSTS Nasdaq
- BLRX Nasdaq
- Market Cap
- NSTS 65.5M
- BLRX 15.3M
- IPO Year
- NSTS N/A
- BLRX 2011
- Fundamental
- Price
- NSTS $12.00
- BLRX $4.70
- Analyst Decision
- NSTS
- BLRX Strong Buy
- Analyst Count
- NSTS 0
- BLRX 2
- Target Price
- NSTS N/A
- BLRX $19.00
- AVG Volume (30 Days)
- NSTS 3.4K
- BLRX 77.4K
- Earning Date
- NSTS 08-08-2025
- BLRX 08-14-2025
- Dividend Yield
- NSTS N/A
- BLRX N/A
- EPS Growth
- NSTS N/A
- BLRX N/A
- EPS
- NSTS N/A
- BLRX N/A
- Revenue
- NSTS $9,115,000.00
- BLRX $22,340,000.00
- Revenue This Year
- NSTS N/A
- BLRX N/A
- Revenue Next Year
- NSTS N/A
- BLRX N/A
- P/E Ratio
- NSTS N/A
- BLRX N/A
- Revenue Growth
- NSTS 78.72
- BLRX 91.68
- 52 Week Low
- NSTS $9.37
- BLRX $2.30
- 52 Week High
- NSTS $13.32
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- NSTS 42.47
- BLRX 57.56
- Support Level
- NSTS $11.90
- BLRX $4.05
- Resistance Level
- NSTS $12.39
- BLRX $4.64
- Average True Range (ATR)
- NSTS 0.18
- BLRX 0.38
- MACD
- NSTS -0.05
- BLRX -0.01
- Stochastic Oscillator
- NSTS 55.06
- BLRX 86.17
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.